Tanja Dowe has a more than 20-year career in the life sciences and biotechnology sectors.
Tanja Dowe has joined Angelini Ventures, the corporate venture arm of Italian industrial company Angelini Industries, as managing director.
Dowe was previously CEO of Debiopharm Innovation Fund, the strategic investment arm of Debiopharm Group, a Swiss biopharmaceutical company. At Debiopharm, Tanja built a portfolio of 17 digital health and data driven R&D tech companies, and consolidated a legacy portfolio of diagnostics investments.
Before her career in start-up investments, Tanja was the Managing Partner of Innomedica Ltd, a boutique strategy and transaction consulting company in life sciences, and a founder-CEO of a market research agency BioSolutions INT.
During her career, Tanja has worked with over 90 HealthTech companies globally, leading to broad experience in innovative product development, commercial strategies, and building winning teams. Tanja is an experienced board member and chairwoman with a track record of successful M&A exits. She holds an MSc in Applied Microbiology and Biochemistry from Helsinki University of Technology (nowadays Aalto University).
About Angelini Ventures
Angelini Ventures, the venture capital arm of Angelini Industries, is an early-stage investment firm focused on accelerating disruptive innovations and trends in digital health and life sciences. The group will invest €300M across a global portfolio led by investment professionals and advisors in Europe, North America, and Asia. Angelini Ventures has deep domain expertise and leverages a global team, advisors, and strategic partners to help entrepreneurs scale their businesses into transformative category-leading companies. www.angeliniventures.com